Processa pharmaceuticals' dr. david young to present at world orphan drug congress usa 2025

Hanover, md., april 15, 2025 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (processa or the company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced that dr. david young, founder and president of research & development, has been invited to present at the world orphan drug congress usa 2025.
PCSA Ratings Summary
PCSA Quant Ranking